Liposomal amikacin dry powder inhaler: Effect of fines on in vitro performance

AAPS PharmSciTech

Volumn 5, Issue 4, 2004, Pages

  Shah, Shrenik P ^a   Misra, Ambikanandan ^a  

^a M S UNIVERSITY OF BARODA   (India)

Author keywords

Amikacin; Dry powder inhalers; Fine particle fraction; Fines; Lactose; Liposomes

Indexed keywords

AMIKACIN; CHOLESTEROL; CRYOPROTECTIVE AGENT; DRUG VEHICLE; LIPOSOME; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLGLYCEROL;

ARTICLE; COMPRESSIVE STRENGTH; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SOLUBILITY; DRY POWDER; FREEZE DRYING; IN VITRO STUDY; LIGHT SCATTERING; POWDER INHALER; SCANNING ELECTRON MICROSCOPY; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; CHEMISTRY; NEBULIZER; POWDER;

AMIKACIN; LIPOSOMES; NEBULIZERS AND VAPORIZERS; POWDERS;

EID: 23144466480     PISSN: 15309932     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/pt050465     Document Type: Article

References (31)

1. Kumana CR, Yuen KY. Parenteral aminoglycoside therapy, selection, administration and monitoring. Drugs. 1994;47:902-913.
2. Molitoris BA. Cell biology of aminoglycoside nephrotoxicity: newer aspects. Curr Opin Nephrol Hypertens. 1997;6:384-388.
3. Senior J. Fate and behavior of liposomes in vivo. Crit Rev Ther Drug Carrier Syst. 1987;3:123-193.
4. Patel HM. Serum opsonins and liposomes: their interaction and opsonophagocytosis. Crit Rev Ther Drug Carrier Syst. 1992; 15:57-88.
5. Ganderton D. The generation of respirable cloud from coarse powder aggregates. J Biopharm Sci. 1992;3:101-105.
6. French DL, Edwards DA, Niven RW. The influence of formulation on emission, deaggregation and deposition of dry powders for inhalation. J Aerosol Sci. 1996;27:769-783.
7. Steckel H, Muller BW. In vitro evaluation of dry powder inhalers II: Influence of carrier particle size and concentration on in vitro deposition. Int J Pharm. 1997;154:31-37.
8. Staniforth JN. Improvement in dry powder inhaler performance: surface passivation effects. In: Proceedings of Drug Delivery to the Lungs VII. The Aerosol Society, London, UK; 1996:86-89.
9. Zeng XM, Tee SK, Martin GP, Marriott C. Effect of mixing procedure and particle size distribution of carrier particles on the deposition of salbutamol sulphate from dry powder inhaler formulations. In: Proceedings of Drug Delivery to the Lungs VII. The Aerosol Society, London, UK; 1996:40-43.
10. Lucas P, Anderson K, Staniforth JN. Protein deposition from dry powder inhalers: fine particle multiplets as performance modifiers. Pharm Res. 1998;15:562-569.
11. Kim JC, Kim JD. Preparation by spray drying of amphotericin B - phospholipid composite particles and their anticellular activity. Drug Deliv. 2001;8:143-147.
12. Farr SJ, Kellaway IW, Carman-Meakin B. Assessing the potential of aerosol generated liposomes from pressurized pack formulations. J Control Release. 1987;5:119-127.
13. McCallion ONM, Taylor KMG, Bridges PA, Thomas M, Taylor AJ. Jet nebulizers for pulmonary drug delivery. Int J Pharm. 1996;130:1-11.
14. Davidson IG, Langner EJ, Plowman SV, Blair JA. Release mechanism of insulin encapsulated in trehalose ester derivative microparticles delivered via inhalation. Int J Pharm. 2003;254:211-222.
15. Alcock R, Blair JA, O'Mahony DJ, Raoof A, Quirk AV. Modifying the release of leuprolide from spray dried OED microparticles. J Control Release. 2002;82:429-440.
16. Fiegel J, Fu J, Hanes J. Poly(ether-anhydride) dry powder aerosols for sustained drug delivery in the lungs. J Control Release. 2004;96:411-423.
17. Surendrakumar K, Martyn GP, Hodgers EC, Jansen M, Blair JA. Sustained release of insulin from sodium hyaluronate based dry powder formulations after pulmonary delivery to beagle dogs. J Control Release. 2003;91:385-394.
18. Sethuraman VV, Hickey AJ. Powder properties and their influence on dry powder inhaler delivery of an antitubercular drug. AAPS PharmSciTech. 2002;3:E28.
19. Fu J, Fiegel J, Krauland E, Hanes J. New polymeric carriers for controlled drug delivery following inhalation or injection. Biomaterials. 2002;23:4425-4433.
20. Joshi M, Misra A. Dry powder inhalation of liposomal Ketotifen fumarate: formulation and characterization. Int J Pharm.2001;223:15-27.
21. Joshi MR, Misra A. Liposomal budesonide for dry powder inhaler: preparation and stabilization. AAPS PharmSciTech. 2001;2:E25.
22. Cortesi R, Esposito E, Gambarin S, Telloli P, Menegatti E, Nastruzzi C. Preparation of liposomes by reverse-phase evaporation using alternative organic solvent. J Microencapsul. 1999;16:251-256.
23. Rizk M, Younis F. Spectrophotometric assay of certain aminoglycoside antibiotics using chloranil. Anal Lett. 1984;17:1803-1809.
24. Carr RL. Evaluating flow properties of solids. Chem Eng. 1965;72:163-168.
25. British Pharmacopoeia Commission. Pressurized inhalations: deposition of the emitted dose. In: British Pharmacopoeia. Vol 2. London, UK: Her Majesty's Stationary Office; 1993:A194-A196.
26. Hino T, Serigano T, Yamamoto H, Takeuchi H, Niwa T, Kawashima Y. Particle design of wogon extract dry powder for inhalation aerosols with granulation method. Int J Pharm. 1998;168:59-68.
27. Betageri GV, Jenkins SA, Parsons DL. Liposome Drug Delivery Systems. Lancaster, PA: Technomic Publishing Company; 1993:16-17.
28. Staniforth JN. Preformulation aspects of dry powder aerosols. In: Byron PR, Dalby RN, Farr SJ, eds. Respiratory Drug Delivery V. Buffalo Grove, IL: Interpharm Press; 1996: 65-73.
29. Gonda I. Physico-chemical principles in aerosol-delivery. In: Crommelin DJA, Midha KK, eds. Topics in Pharmaceutical Sciences. Stuttgart, Germany: Medipharm Scientific Publishers: 1992 : 95-115.
30. Hickey AJ. Inhalation Aerosols - Physical and Biological Basis for Therapy. New York, NY: Marcel Dekker Inc; 1996:441-473.
31. Hamaker HC. London-van der Waals forces attraction between spherical particles. Physica (Utrecht). 1937;4:1058-1072.